Fair Value Measurements - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Feb. 28, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total unrealized gains recorded in accumulated other comprehensive income (loss)	$ 8,400,000	$ 900,000
Accrued interest receivable excluded from fair value and amortized cost basis of available for sale securities	2,500,000	1,100,000
Write off of accrued interest receivable	0	0
Estimated fair value of contingent consideration	1,500,000	5,700,000
Brii Bio Parent [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investment Owned At Fair Value	31,900,000
Increase Decrease In Equity Securities Fv Ni	111,100,000
Foreign Currency Transaction Gain Loss Unrealized	$ 100,000
Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Securities contractual term	2 years
Humabs
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Estimated fair value of contingent consideration	$ 23,400,000	$ 17,100,000
Contingent Consideration Liability | TomegaVax Letter Agreement | TomegaVax
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Asset acquisition milestone achieved			$ 10,000,000.0